On Tuesday morning, biotech company Loyal announced that it had reached a key milestone in the path toward approval of its lifespan-extending drug for big dogs.
The announcement came after the Food and Drug Administration (FDA) Center for Veterinary Medicine confirmed that Loyal’s data (all 2,300 pages of it, according to CEO Celine Halioua) met a key requirement for the…